Related Experiment Video
Updated: Nov 1, 2025
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
A smart multiantenna gene theranostic system based on the programmed assembly of hypoxia-related siRNAs
Xue Gong1, Haizhou Wang2, Ruomeng Li1
1Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, P. R. China.
Abstract:
The systemic therapeutic utilisation of RNA interference (RNAi) is limited by the non-specific off-target effects, which can have severe adverse impacts in clinical applications. The accurate use of RNAi requires tumour-specific on-demand conditional activation to eliminate the off-target effects of RNAi, for which conventional RNAi systems cannot be used. Herein, a tumourous biomarker-activated RNAi platform is achieved through the careful design of RNAi prodrugs in extracellular vesicles (EVs) with cancer-specific recognition/activation features. These RNAi prodrugs are assembled by splitting and reconstituting the principal siRNAs into a hybridisation chain reaction (HCR) amplification machine. EVs facilitate the specific and efficient internalisation of RNAi prodrugs into target tumour cells, where endogenous microRNAs (miRNAs) promote immediate and autonomous HCR-amplified RNAi activation to simultaneously silence multiantenna hypoxia-related genes. With multiple guaranteed cancer recognition and synergistic therapy features, the miRNA-initiated HCR-promoted RNAi cascade holds great promise for personalised theranostics that enable reliable diagnosis and programmable on-demand therapy.
Insights
This study introduces a novel RNA interference (RNAi) platform using extracellular vesicles to activate RNAi specifically in tumors. This approach minimizes off-target effects for safer, more effective cancer therapy.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Therapeutics
Background:
- Systemic RNA interference (RNAi) therapy is hindered by non-specific off-target effects, limiting clinical applications.
- Accurate RNAi requires tumor-specific, on-demand activation to mitigate adverse impacts.
Purpose of the Study:
- To develop a tumor biomarker-activated RNAi platform for enhanced safety and efficacy.
- To engineer RNAi prodrugs within extracellular vesicles (EVs) for targeted cancer therapy.
Main Methods:
- Designed RNAi prodrugs using a hybridization chain reaction (HCR) amplification system.
- Encapsulated prodrugs in EVs for cancer-specific recognition and internalization.
- Utilized endogenous microRNAs (miRNAs) for autonomous HCR-amplified RNAi activation within tumor cells.
Main Results:
- Achieved tumor-specific activation of RNAi, silencing multiple hypoxia-related genes simultaneously.
- Demonstrated efficient internalization of RNAi prodrugs into target tumor cells via EVs.
- Showcased autonomous, HCR-amplified RNAi triggered by endogenous miRNAs.
Conclusions:
- The developed miRNA-initiated HCR-promoted RNAi cascade offers a promising strategy for personalized cancer theranostics.
- This platform enables reliable diagnosis and programmable, on-demand therapy with reduced off-target effects.
- The system integrates cancer recognition and synergistic therapeutic features for advanced treatment modalities.
More Related Videos
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi